Skip to main content

Table 3 Patient-reported outcomes at W8 compared to D0

From: Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study

Outcome

D0

W8

p value

Pain/dyspareunia VAS (N20)

VAS

   

 Median

7.25

0

p = 0.0001

 IQR

3.5; 8.25

0; 3.25

 

 Range

0; 10

0; 10

 

Number of women reporting Dyspareunia (N = 20)

Suffer with Dyspareunia

16

8

p = 0.0078

Number of women reporting Vaginal dryness (N = 20)

Suffer with dryness

16

2

p = 0.0005

Number of women reporting Vaginal Chaffing (N = 20)

Suffer with chaffing

10

2

p = 0.0215

Number of women reporting Vulvar pruritus (N = 20)

Suffering with pruritus

7

1

p = 0.0313

Female sexual function index (FSFI) scores

Full scale

 Median

18.8

24.65

p = 0.0019

 IQR

15.7; 21.9

19.9; 28.7

 

 Range

2; 28.8

4.8; 34.5

 

Desire domain

 Median

3

3.6

p = 0.0010

 IQR

1.8; 3.6

2.7; 4.2

 

 Range

1.2; 4.2

1.8; 5.4

 

Arousal domain

 Median

3

4.2

p = 0.0549

 IQR

1.5; 4.5

2.55; 4.8

 

 Range

0; 5.1

0; 5.7

 

Lubrication domain

 Median

2.4

4.65

p = 0.0005

 IQR

0.6; 3

3.75; 5.1

 

 Range

0; 6

0; 6

 

Orgasm domain

 Median

3.8

4.8

p = 0.3515

 IQR

0.6; 5.6

1.8; 5.6

 

 Range

0; 6

0; 6

 

Satisfaction domain

 Median

4

5.2

p = 0.0126

 IQR

2.8; 4.8

4; 5.6

 

 Range

0.8; 6

1.2; 6

 

Pain domain*

 Median

1.6

3.6

p = 0.0005

 IQR

0; 3.6

1.2; 5.4

 

 Range

0; 4.8

0; 6

 
  1. *A higher score indicates less pain